Rola lakozamidu i lewetyracetamu w leczeniu padaczki Artykuł przeglądowy
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
cze 30, 2023
Słowa kluczowe:
bezpieczeństwo, monoterapia, politerapia, lekooporność, padaczka, padaczka ogniskowa
##plugins.themes.bootstrap3.article.main##
Abstrakt
Lewetyracetam i lakozamid są lekami nowymi, o nieco innych niż klasyczne preparaty mechanizmach działania. Lewetyracetam hamuje przewodnictwo synaptyczne przez blokowanie wydzielania pęcherzyków synaptycznych. Lakozamid zwiększa liczbę nieaktywnych kanałów sodowych, co prowadzi do zmniejszenia pobudliwości neuronów. Oba leki można stosować w monoterapii, a także łączyć niemal z każdym lekiem przeciwnapadowym ze względu na synergizm działania oraz niewielką liczbę interakcji. Ze względu na korzystny profil terapeutyczny i brak wpływu na zdolności poznawcze są szczególnie godne polecenia w politerapii i u osób starszych, osób niepełnosprawnych oraz u dzieci.
##plugins.themes.bootstrap3.article.details##
Jak cytować
Kurkowska-Jastrzębska, I. (2023). Rola lakozamidu i lewetyracetamu w leczeniu padaczki . Medycyna Faktów , 16(2(59), 170-174. https://doi.org/10.24292/01.MF.0223.07
Numer
Dział
Artykuły
Copyright © by Medical Education. All rights reserved.
Bibliografia
1. Rejdak K, Rola R, Mazurkiewicz-Bełdzińska M et al. Diagnostyka i leczenie padaczki – wytyczne Sekcji Padaczki Polskiego Towarzystwa Neurologicznego. Pol Przegl Neurol. 2020; 16(3): 129-44.
2. Lyseng-Williamson KA. Levetiracetam: a review of its use in epilepsy. Drugs. 2011; 71(4): 489-514. http://doi.org/10.2165/11204490-000000000-00000.
3. Pawlik MJ, Miziak B, Walczak A et al. Selected Molecular Targets for Antiepileptogenesis. Int J Mol Sci. 2021; 22(18): 9737.
4. Dudra-Jastrzebska M, Andres-Mach MM, Sielski M et al. Pharmacodynamic and pharmacokinetic interaction profiles of levetiracetam in combination with gabapentin, tiagabine and vigabatrin in the mouse pentylenetetrazole-induced seizure model: an isobolographic analysis. Eur J Pharmacol. 2009; 605: 87-94. http://doi.org/10.1016/j.ejphar.2008.12.046.
5. Florek-Luszczki M, Wlaz A, Luszczki JJ. Interactions of levetiracetam with carbamazepine, phenytoin, topiramate and vigabatrin in the mouse 6 Hz psychomotor seizure model – a type II isobolographic analysis. Eur J Pharmacol. 2014; 723: 410-8. http://doi.org/10.1016/j.ejphar.2013.10.063.
6. European Medicines Agency. Vimpat (Lacosamide). EMA Summary of Product Characteristics. Brussels, BE: UCB Pharma SA; 2017.
7. Villanueva V, Giraldez BG, Toledo M et al. Lacosamide monotherapy in clinical practice: A retrospective chart review. Acta Neurol Scand. 2018; 138(3): 186-94.
8. Ortiz de la Rosa JS, Ladino LD, Rodriguez PJ et al. Efficacy of lacosamide in children and adolescents with drug-resistant epilepsy and refractory status epilepticus: A systematic review. Seizure. 2018; 56: 34-40.
9. Rogawski MA, Tofighy A, White HS et al. Current understanding of the mechanism of action of the antiepileptic drug lacosamide. Epilepsy Res. 2015; 110: 189-205.
10. Ruffolo G, Di Bonaventura C, Cifelli P et al. A novel action of lacosamide on GABAA currents sets the ground for a synergic interaction with levetiracetam in treatment of epilepsy. Neurobiol Dis. 2018; 115: 59-68.
11. Rosati A, Ilvento L, Rizzi R et al. Long-term efficacy of add-on lacosamide treatment in children and adolescents with refractory epilepsies: a single- center observational study. Epilepsia. 2018; 59(5): 1004-10.
12. Neal A, D’Souza W, Hepworth G et al. Efficacy and tolerability of adjuvant lacosamide: the role of clinical characteristics and mechanisms of action of concomitant AEDs. Epilepsy Behav. 2018; 80: 25-32.
13. McGinnis E, Kessler SK. Lacosamide use in children with epilepsy: Retention rate and effect of concomitant sodium channel blockers in a large cohort Epilepsia. 2016; 57(9): 1416-25.
14. Kleist A, Kerling F, Hamer H et al. Lacosamide in patients with intellectual disability and refractory epilepsy. Acta Neurol Belg. 2019; 119(3): 423-30.
15. Shandra A, Shandra P, Kaschenko O. Synergism of lacosamide with established antiepileptic drugs in the 6-Hz seizure model in mice. Epilepsia. 2013; 54(7): 1167-75.
16. Yang C, Peng Y, Zhang L et al. Safety and Tolerability of Lacosamide in Patients With Epilepsy: A Systematic Review and Meta-Analysis. Front Pharmacol. 2021; 12: 694381. http://doi.org/10.3389/fphar.2021.694381.
17. Nevitt SJ, Sudell M, Weston J et al. Antiepileptic drug monotherapy for epilepsy: a network meta-analysis of individual participant data. Cochrane Database Syst Rev. 2017; 12(12): CD011412. http://doi.org/10.1002/14651858.
18. Kalilani L, Lu C, Pierre-Louis B et al. Lacosamide and concomitant use of antiepileptic and other medications in a US population – A retrospective cohort study. Epilepsy Behav. 2017; 72: 51-7.
19. Lezaic N, Gore G, Josephson CB et al. The medical treatment of epilepsy in the elderly: a systematic review and meta-analysis. Epilepsia. 2019; 60: 1325-40.
20. Lattanzi S, Trinka E, Del Giovane C et al. Antiepileptic drug monotherapy for epilepsy in the elderly: a systematic review and network meta- analysis. Epilepsia. 2019; 60: 2245-54.
21. Sanchez PE, Zhu L, Verret L et al. Levetiracetam suppresses neuronal network dysfunction and reverses synaptic and cognitive deficits in an Alzheimer’s disease model. Proc Natl Acad Sci USA. 2012; 109: e2895-903.
22. ILiAD study; NCT03489044.
23. Pozzi M, Zanotta N, Epifanio R et al. Lacosamide effectiveness and tolerability in patients with drug-resistant epilepsy and severe disability under polytherapy: Therapy optimization as emerging from an observational study. Epilepsy Behav. 2022; 128: 108598. http://doi.org/10.1016/j.yebeh.2022.108598.
24. Mäkinen J, Peltola J, Raitanen J et al. Comparative effectiveness of eight antiepileptic drugs in adults with focal refractory epilepsy: the influence of age, gender, and the sequence in which drugs were introduced onto the market. J Neurol. 2017; 264(7): 1345-53. http://doi.org/10.1007/s00415-017-8526-8.n.
25. Lyseng-Williamson KA. Levetiracetam: a review of its use in epilepsy. Drugs. 2011; 71(4): 489-514. http://doi.org/10.2165/11204490-000000000-00000.
26. Rosati A, Ilvento L, Lucenteforte E et al. Comparative efficacy of antiepileptic drugs in children and adolescents: A network meta-analysis. Epilepsia. 2018; 59(2): 297-314. http://doi.org/10.1111/epi.13981.
27. Kim HJ, Kim SH, Kang HC et al. Adjunctive levetiracetam treatment in pediatric Lennox-Gastaut syndrome. Pediatr Neurol. 2014; 51(4): 527-31. http://doi.org/10.1016/j.pediatrneurol.2014.06.004.
28. Kwan P, Arzimanoglou A, Berg AT et al. Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia. 2010; 51: 1069-77.
29. Keezer MR, Sisodiya SM, Sander JW. Comorbidities of epilepsy: current concepts and future perspectives. Lancet Neurol. 2016; 15(1): 106-15. http://doi.org/10.1016/S1474-4422(15)00225-2.
30. Verrotti A, Lattanzi S, Brigo F et al. Pharmacodynamic interactions of antiepileptic drugs: From bench to clinical practice. Epilepsy Behav. 2020; 104(Pt A): 106939. http://doi.org/10.1016/j.yebeh.2020.106939.
31. Liu A, Gu Q, Wang M. Effects of levetiracetam and lacosamide on therapeutic efficacy and neural function in patients with epilepsy. Exp Ther Med. 2020; 20(4): 3687-94. http://doi.org/10.3892/etm.2020.9126.
2. Lyseng-Williamson KA. Levetiracetam: a review of its use in epilepsy. Drugs. 2011; 71(4): 489-514. http://doi.org/10.2165/11204490-000000000-00000.
3. Pawlik MJ, Miziak B, Walczak A et al. Selected Molecular Targets for Antiepileptogenesis. Int J Mol Sci. 2021; 22(18): 9737.
4. Dudra-Jastrzebska M, Andres-Mach MM, Sielski M et al. Pharmacodynamic and pharmacokinetic interaction profiles of levetiracetam in combination with gabapentin, tiagabine and vigabatrin in the mouse pentylenetetrazole-induced seizure model: an isobolographic analysis. Eur J Pharmacol. 2009; 605: 87-94. http://doi.org/10.1016/j.ejphar.2008.12.046.
5. Florek-Luszczki M, Wlaz A, Luszczki JJ. Interactions of levetiracetam with carbamazepine, phenytoin, topiramate and vigabatrin in the mouse 6 Hz psychomotor seizure model – a type II isobolographic analysis. Eur J Pharmacol. 2014; 723: 410-8. http://doi.org/10.1016/j.ejphar.2013.10.063.
6. European Medicines Agency. Vimpat (Lacosamide). EMA Summary of Product Characteristics. Brussels, BE: UCB Pharma SA; 2017.
7. Villanueva V, Giraldez BG, Toledo M et al. Lacosamide monotherapy in clinical practice: A retrospective chart review. Acta Neurol Scand. 2018; 138(3): 186-94.
8. Ortiz de la Rosa JS, Ladino LD, Rodriguez PJ et al. Efficacy of lacosamide in children and adolescents with drug-resistant epilepsy and refractory status epilepticus: A systematic review. Seizure. 2018; 56: 34-40.
9. Rogawski MA, Tofighy A, White HS et al. Current understanding of the mechanism of action of the antiepileptic drug lacosamide. Epilepsy Res. 2015; 110: 189-205.
10. Ruffolo G, Di Bonaventura C, Cifelli P et al. A novel action of lacosamide on GABAA currents sets the ground for a synergic interaction with levetiracetam in treatment of epilepsy. Neurobiol Dis. 2018; 115: 59-68.
11. Rosati A, Ilvento L, Rizzi R et al. Long-term efficacy of add-on lacosamide treatment in children and adolescents with refractory epilepsies: a single- center observational study. Epilepsia. 2018; 59(5): 1004-10.
12. Neal A, D’Souza W, Hepworth G et al. Efficacy and tolerability of adjuvant lacosamide: the role of clinical characteristics and mechanisms of action of concomitant AEDs. Epilepsy Behav. 2018; 80: 25-32.
13. McGinnis E, Kessler SK. Lacosamide use in children with epilepsy: Retention rate and effect of concomitant sodium channel blockers in a large cohort Epilepsia. 2016; 57(9): 1416-25.
14. Kleist A, Kerling F, Hamer H et al. Lacosamide in patients with intellectual disability and refractory epilepsy. Acta Neurol Belg. 2019; 119(3): 423-30.
15. Shandra A, Shandra P, Kaschenko O. Synergism of lacosamide with established antiepileptic drugs in the 6-Hz seizure model in mice. Epilepsia. 2013; 54(7): 1167-75.
16. Yang C, Peng Y, Zhang L et al. Safety and Tolerability of Lacosamide in Patients With Epilepsy: A Systematic Review and Meta-Analysis. Front Pharmacol. 2021; 12: 694381. http://doi.org/10.3389/fphar.2021.694381.
17. Nevitt SJ, Sudell M, Weston J et al. Antiepileptic drug monotherapy for epilepsy: a network meta-analysis of individual participant data. Cochrane Database Syst Rev. 2017; 12(12): CD011412. http://doi.org/10.1002/14651858.
18. Kalilani L, Lu C, Pierre-Louis B et al. Lacosamide and concomitant use of antiepileptic and other medications in a US population – A retrospective cohort study. Epilepsy Behav. 2017; 72: 51-7.
19. Lezaic N, Gore G, Josephson CB et al. The medical treatment of epilepsy in the elderly: a systematic review and meta-analysis. Epilepsia. 2019; 60: 1325-40.
20. Lattanzi S, Trinka E, Del Giovane C et al. Antiepileptic drug monotherapy for epilepsy in the elderly: a systematic review and network meta- analysis. Epilepsia. 2019; 60: 2245-54.
21. Sanchez PE, Zhu L, Verret L et al. Levetiracetam suppresses neuronal network dysfunction and reverses synaptic and cognitive deficits in an Alzheimer’s disease model. Proc Natl Acad Sci USA. 2012; 109: e2895-903.
22. ILiAD study; NCT03489044.
23. Pozzi M, Zanotta N, Epifanio R et al. Lacosamide effectiveness and tolerability in patients with drug-resistant epilepsy and severe disability under polytherapy: Therapy optimization as emerging from an observational study. Epilepsy Behav. 2022; 128: 108598. http://doi.org/10.1016/j.yebeh.2022.108598.
24. Mäkinen J, Peltola J, Raitanen J et al. Comparative effectiveness of eight antiepileptic drugs in adults with focal refractory epilepsy: the influence of age, gender, and the sequence in which drugs were introduced onto the market. J Neurol. 2017; 264(7): 1345-53. http://doi.org/10.1007/s00415-017-8526-8.n.
25. Lyseng-Williamson KA. Levetiracetam: a review of its use in epilepsy. Drugs. 2011; 71(4): 489-514. http://doi.org/10.2165/11204490-000000000-00000.
26. Rosati A, Ilvento L, Lucenteforte E et al. Comparative efficacy of antiepileptic drugs in children and adolescents: A network meta-analysis. Epilepsia. 2018; 59(2): 297-314. http://doi.org/10.1111/epi.13981.
27. Kim HJ, Kim SH, Kang HC et al. Adjunctive levetiracetam treatment in pediatric Lennox-Gastaut syndrome. Pediatr Neurol. 2014; 51(4): 527-31. http://doi.org/10.1016/j.pediatrneurol.2014.06.004.
28. Kwan P, Arzimanoglou A, Berg AT et al. Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia. 2010; 51: 1069-77.
29. Keezer MR, Sisodiya SM, Sander JW. Comorbidities of epilepsy: current concepts and future perspectives. Lancet Neurol. 2016; 15(1): 106-15. http://doi.org/10.1016/S1474-4422(15)00225-2.
30. Verrotti A, Lattanzi S, Brigo F et al. Pharmacodynamic interactions of antiepileptic drugs: From bench to clinical practice. Epilepsy Behav. 2020; 104(Pt A): 106939. http://doi.org/10.1016/j.yebeh.2020.106939.
31. Liu A, Gu Q, Wang M. Effects of levetiracetam and lacosamide on therapeutic efficacy and neural function in patients with epilepsy. Exp Ther Med. 2020; 20(4): 3687-94. http://doi.org/10.3892/etm.2020.9126.